Estrogen plus progestin therapy and breast cancer in recently postmenopausal women

Ross L. Prentice, Rowan T. Chlebowski, Marcia L. Stefanick, Joann E. Manson, Mary Pettinger, Susan L. Hendrix, F. Allan Hubbell, Charles Kooperberg, Lewis H. Kuller, Dorothy S. Lane, Anne McTiernan, Mary Jo O'Sullivan, Jacques E. Rossouw, Garnet L. Anderson

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The Women's Health Initiative trial found a modestly increased risk of invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among women who had previously received postmenopausal hormone therapy. In comparison, observational studies mostly report a larger risk increase. To explain these patterns, the authors examined the effects of this regimen in relation to both prior hormone therapy and time from menopause to first use of postmenopausal hormone therapy ("gap time") in the Women's Health Initiative trial and in a corresponding subset of the Women's Health Initiative observational study. Postmenopausal women with a uterus enrolled at 40 US clinical centers during 1993-1998. The authors found that hazard ratios agreed between the two cohorts at a specified gap time and time from hormone therapy initiation. Combined trial and observational study data support an adverse effect on breast cancer risk. Women who initiate use soon after menopause, and continue for many years, appear to be at particularly high risk. For example, for a woman who starts soon after menopause and adheres to this regimen, estimated hazard ratios are 1.64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use.

Original languageEnglish
Pages (from-to)1207-1216
Number of pages10
JournalAmerican Journal of Epidemiology
Volume167
Issue number10
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Progestins
Estrogens
Women's Health
Menopause
Hormones
Breast Neoplasms
Observational Studies
Confidence Intervals
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Therapeutics
Uterus

Keywords

  • Breast neoplasms
  • Clinical trials as topic
  • Cohort studies
  • Estrogens
  • Hormone replacement therapy
  • Postmenopause
  • Progestins

ASJC Scopus subject areas

  • Epidemiology

Cite this

Prentice, R. L., Chlebowski, R. T., Stefanick, M. L., Manson, J. E., Pettinger, M., Hendrix, S. L., ... Anderson, G. L. (2008). Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. American Journal of Epidemiology, 167(10), 1207-1216. https://doi.org/10.1093/aje/kwn044

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. / Prentice, Ross L.; Chlebowski, Rowan T.; Stefanick, Marcia L.; Manson, Joann E.; Pettinger, Mary; Hendrix, Susan L.; Hubbell, F. Allan; Kooperberg, Charles; Kuller, Lewis H.; Lane, Dorothy S.; McTiernan, Anne; Jo O'Sullivan, Mary; Rossouw, Jacques E.; Anderson, Garnet L.

In: American Journal of Epidemiology, Vol. 167, No. 10, 01.05.2008, p. 1207-1216.

Research output: Contribution to journalArticle

Prentice, RL, Chlebowski, RT, Stefanick, ML, Manson, JE, Pettinger, M, Hendrix, SL, Hubbell, FA, Kooperberg, C, Kuller, LH, Lane, DS, McTiernan, A, Jo O'Sullivan, M, Rossouw, JE & Anderson, GL 2008, 'Estrogen plus progestin therapy and breast cancer in recently postmenopausal women', American Journal of Epidemiology, vol. 167, no. 10, pp. 1207-1216. https://doi.org/10.1093/aje/kwn044
Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. American Journal of Epidemiology. 2008 May 1;167(10):1207-1216. https://doi.org/10.1093/aje/kwn044
Prentice, Ross L. ; Chlebowski, Rowan T. ; Stefanick, Marcia L. ; Manson, Joann E. ; Pettinger, Mary ; Hendrix, Susan L. ; Hubbell, F. Allan ; Kooperberg, Charles ; Kuller, Lewis H. ; Lane, Dorothy S. ; McTiernan, Anne ; Jo O'Sullivan, Mary ; Rossouw, Jacques E. ; Anderson, Garnet L. / Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. In: American Journal of Epidemiology. 2008 ; Vol. 167, No. 10. pp. 1207-1216.
@article{0d5cb58deea2493b98c2cdf4b3cf6aa3,
title = "Estrogen plus progestin therapy and breast cancer in recently postmenopausal women",
abstract = "The Women's Health Initiative trial found a modestly increased risk of invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among women who had previously received postmenopausal hormone therapy. In comparison, observational studies mostly report a larger risk increase. To explain these patterns, the authors examined the effects of this regimen in relation to both prior hormone therapy and time from menopause to first use of postmenopausal hormone therapy ({"}gap time{"}) in the Women's Health Initiative trial and in a corresponding subset of the Women's Health Initiative observational study. Postmenopausal women with a uterus enrolled at 40 US clinical centers during 1993-1998. The authors found that hazard ratios agreed between the two cohorts at a specified gap time and time from hormone therapy initiation. Combined trial and observational study data support an adverse effect on breast cancer risk. Women who initiate use soon after menopause, and continue for many years, appear to be at particularly high risk. For example, for a woman who starts soon after menopause and adheres to this regimen, estimated hazard ratios are 1.64 (95{\%} confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95{\%} confidence interval: 1.56, 3.08) over a 10-year period of use.",
keywords = "Breast neoplasms, Clinical trials as topic, Cohort studies, Estrogens, Hormone replacement therapy, Postmenopause, Progestins",
author = "Prentice, {Ross L.} and Chlebowski, {Rowan T.} and Stefanick, {Marcia L.} and Manson, {Joann E.} and Mary Pettinger and Hendrix, {Susan L.} and Hubbell, {F. Allan} and Charles Kooperberg and Kuller, {Lewis H.} and Lane, {Dorothy S.} and Anne McTiernan and {Jo O'Sullivan}, Mary and Rossouw, {Jacques E.} and Anderson, {Garnet L.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1093/aje/kwn044",
language = "English",
volume = "167",
pages = "1207--1216",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Estrogen plus progestin therapy and breast cancer in recently postmenopausal women

AU - Prentice, Ross L.

AU - Chlebowski, Rowan T.

AU - Stefanick, Marcia L.

AU - Manson, Joann E.

AU - Pettinger, Mary

AU - Hendrix, Susan L.

AU - Hubbell, F. Allan

AU - Kooperberg, Charles

AU - Kuller, Lewis H.

AU - Lane, Dorothy S.

AU - McTiernan, Anne

AU - Jo O'Sullivan, Mary

AU - Rossouw, Jacques E.

AU - Anderson, Garnet L.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The Women's Health Initiative trial found a modestly increased risk of invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among women who had previously received postmenopausal hormone therapy. In comparison, observational studies mostly report a larger risk increase. To explain these patterns, the authors examined the effects of this regimen in relation to both prior hormone therapy and time from menopause to first use of postmenopausal hormone therapy ("gap time") in the Women's Health Initiative trial and in a corresponding subset of the Women's Health Initiative observational study. Postmenopausal women with a uterus enrolled at 40 US clinical centers during 1993-1998. The authors found that hazard ratios agreed between the two cohorts at a specified gap time and time from hormone therapy initiation. Combined trial and observational study data support an adverse effect on breast cancer risk. Women who initiate use soon after menopause, and continue for many years, appear to be at particularly high risk. For example, for a woman who starts soon after menopause and adheres to this regimen, estimated hazard ratios are 1.64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use.

AB - The Women's Health Initiative trial found a modestly increased risk of invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate, with most evidence among women who had previously received postmenopausal hormone therapy. In comparison, observational studies mostly report a larger risk increase. To explain these patterns, the authors examined the effects of this regimen in relation to both prior hormone therapy and time from menopause to first use of postmenopausal hormone therapy ("gap time") in the Women's Health Initiative trial and in a corresponding subset of the Women's Health Initiative observational study. Postmenopausal women with a uterus enrolled at 40 US clinical centers during 1993-1998. The authors found that hazard ratios agreed between the two cohorts at a specified gap time and time from hormone therapy initiation. Combined trial and observational study data support an adverse effect on breast cancer risk. Women who initiate use soon after menopause, and continue for many years, appear to be at particularly high risk. For example, for a woman who starts soon after menopause and adheres to this regimen, estimated hazard ratios are 1.64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use.

KW - Breast neoplasms

KW - Clinical trials as topic

KW - Cohort studies

KW - Estrogens

KW - Hormone replacement therapy

KW - Postmenopause

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=43249111337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249111337&partnerID=8YFLogxK

U2 - 10.1093/aje/kwn044

DO - 10.1093/aje/kwn044

M3 - Article

VL - 167

SP - 1207

EP - 1216

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 10

ER -